InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
+2.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Mulroy Michael H., Director. Director active across 1 company, notably Lineage Cell Therapeutics, Inc.. In total, 4 reports have been logged. Breakdown: 2 buys · 0 sell. Total volume traded: €31k. History available since 18 June 2021. The latest transaction was disclosed on 22 November 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations4 total
40,000 shares@ US$0.56617.8% of flowCommon SharesSEC:0000950170-24-130592:0
Ideal exit: 19 Aug 2025 (T+270)
7,000 shares@ US$1.400.0022% mcap8.9% of flowCommon Shares, no par valueSEC:0001493152-22-007754:0
Ideal exit: 19 Dec 2022 (T+270)
24,720 shares@ US$2.2037.5% of flowCommon Shares, no par valueSEC:0001493152-21-014860
24,720 shares@ US$2.200.011% mcap45.6% of flowCommon Shares, no par valueSEC:0001493152-21-014860:0
4 of 4 declarations
About Mulroy Michael H.
Michael H. Mulroy is a Board Member at Lineage Cell Therapeutics, Inc. With expertise in the biotechnology sector, he oversees the development and innovation strategies of the company. His role is crucial in ensuring the growth and sustainability of Lineage.
